ITRI is dedicated to develop key ingredients and proper compositions with the state-of art microfluidic technology to set up a non-viral drug delivering platform, which can produce LNP with various types of nucleic acids. As showing by current trends in drug development, this platform can be applied to tackle a broad spectrum of diseases, such as cancer, infectious diseases, chronic diseases, rare diseases, etc. by coupling with different biologically active nucleic acids.